Drug interactions in epilepsy care: perspective on the newer generation antiepileptic drugs

References

• Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W The influence of food on the disposition of the anti-epileptic oxcarbazepine and its major metabolite in healthy volunteers. Biopharm. Drug Dispos. 15(6), 519–526 (1994).
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 36, S7—S9 (1995).
   PubMed Web of Science ®Google Scholar
• Welty TE, Gidal BE, Ficker DM, Privitera MD. Levetiracetam: A different approach to the pharmacotherapy of epilepsy. Ann. Pharmacother. 36,296–304 (2000).
   Web of Science ®Google Scholar
• Gidal BE, DeCerce J, Bockbrader HN et al. Gabapentin bioavailability: efficacy of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31(2) 91–99 (1998).
   Google Scholar
• Gidal BE, Maly MM, Kowalski JVV et al. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. Ann. Pharmacother 32(4) 405–409 (1998).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Maly MM, Budde J, Pitterle ME, Lensmeyer GL, Jones JC. Effect of a high protein meal upon gabapentin pharmacokinetics. Epilepsy Res. 23,71–76 (1996).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40(2-3), 123–127 (2000).
   Google Scholar
• Gustayson LE, Cato A 3rd, Boellner SW et al. Lack of phamracokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am. j Ther. 5(1), 9–16 (1998).
   Google Scholar
• Gustayson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Am. j Ther. (2), 73–79 (1998).
   Google Scholar
• Perruca E, Richens A. General priciples: biotransformation. In: Anti-epileptic drugs. (4th ed). Levy RH, Mattson RH, Meldrum BS (Eds), Raven Press, New York, USA, 31–50 (1995).
   Google Scholar
• ••Good fundamental review of drugmetabolism and enzyme induction.
   Google Scholar
• Benedetti MS. Enzyme induction and inhibition by new anti-epileptic drugs: a review of human studies. Fundamen. Clin. PharmacoL 14(4), 301–319 (2000).
   Google Scholar
• •• Good additional reference on drug interaction data for newer AEDs.
   Google Scholar
• Wagner ML, Remmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its major metabolites. Clin. PharmacoL Ther. 53,536–543 (1993).
   PubMed Web of Science ®Google Scholar
• Hulsman JA, Rentmeester TW, Banfield CR et al. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Clin. PharmacoL Ther 58(4), 383–389 (1995).
   PubMed Web of Science ®Google Scholar
• Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 32,398–406 (1991).
   PubMed Web of Science ®Google Scholar
• Saano V, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin. PharmacoL Ther. 58,523–531 (1995).
   PubMed Web of Science ®Google Scholar
• Anderson GD, Yau MK, Gidal BE et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. PharmacoL Ther. 60,145–156 (1996).
   PubMed Web of Science ®Google Scholar
• Pisani F, Xiao B, Faziop A, Spina E, Perucca E, Tomson T. Single-dose pharmacokinetics of CBZ-E in patients on lamotrigine monotherapy. Epilepsy Res.19,245–248 (1994).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Rutecki P, Shaw R, Maly MM, Collins DM, Pitterle ME. Effect of lamotrigine on carbamazepine epoxide/ carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res 28,207–211 (1997).
   PubMed Web of Science ®Google Scholar
• Anderson GD, Gidal BE, Messenheimer J, Gilliam F. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res. 49,211–217 (2002).
   PubMed Web of Science ®Google Scholar
• •This paper discusses the pharmacokinetic concept of deinduction.
   Google Scholar
• Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 47(1-2), 151–154 (2001).
   Google Scholar
• Nicolas JM, Collart P, Germ n B eta], hz vitro evaluation of potential drug interactions with levetiracetam, a new anti-epileptic agent. Drug Metab. Dispos. 27(2), 250–254 (1999).
   PubMed Web of Science ®Google Scholar
• Perucca E, Gidal BE et al. Lack of pharmacokinetic interaction between levatiracetam and other AEDs. Epilepsia 41, (abstract), (2000).
   Google Scholar
• Llyod P, Flesch G, Dieterle W Clinical pharmacology and phamracokinetics of oxcarbazepine. Epilepsia 35 (Suppl. 3), S10-13 (1994).
   Google Scholar
• Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Potential interaction between oxcarbazepine and an oral contraceptive. Epilepsia 33,1149–1152 (1992).
   Google Scholar
• Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felopidine. Ther Drug Monit 15,39–42 (1993).
   PubMed Web of Science ®Google Scholar
• May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methosuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther. Drug Monit. 21(2), 175–181 (1999).
   Google Scholar
• McKee PJ, Blacklaw J, Forrest Get al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. j Clin. PharmacoL 37(1), 27–32 (1994).
   Google Scholar
• Tartara A, Galimberti CA, Manni R et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbamazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br. j Clin. PharmacoL 36,366–368 (1993).
   Google Scholar
• Kramer G, Tettenborn B, Klosterkov-Jensen P, Menge GP, Stoll KD. Oxcarbazepine does not effect the anticoagulant activity of warfarin. Epilepsia 33,1145–1148 (1992).
   Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer anti-epileptic drugs. Clin. Pharmacokin. 31,29–46 (1996).
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38(3), 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Rimmer EM, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 189–190 (1984).
   Google Scholar
• Dalla Bernardina B, Fontana E, Vigevano F et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 36,687–691 (1995).
   PubMed Web of Science ®Google Scholar
• Ojeman LM, Shastri RA, Wilensky AJ et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther. Drug Monit. 8,293-296 (1986).
   Google Scholar
• Reidenberg P, Glue P, Banfield C et al. Pharmacokinetic interaction studies between felbamate and vigabatrin. Br. Clin. Pharmacol 40(2), 157–160 (1995).
   Google Scholar
• Gidal BE, Kanner A, Maly M, Rutecki P, Lensmeyer GL. Lamotrigine pharmacokinetics in patients receiving felbamate. Epilepsy Res. 27(1), 1–5 (1997).
   PubMed Web of Science ®Google Scholar
• Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 30,225–229 (1989).
   PubMed Web of Science ®Google Scholar
• Wagner ML, Graves NM, Leppik IE et al The effects of felbamate on valproic acid disposition. Clin. PharmacoL Ther. 56, 494–502 (1994).
   PubMed Web of Science ®Google Scholar
• Hooper WD, Franklin ME, Glue P et al. Effect of felbamate on valproic acid dispostion in healthy volunteers: inhibition of B-oxidation. Epilepsia 37,91-97 (1996). aoGidal BE, Sheth RJ, Parnell J. Evaluation of the valproic acid-lamotrigine pharmacokinetic interaction: Relationship to valproate dose and serum concentration in healthy volunteers. Neurology 56, A331 (Abstract) (2001).
   Google Scholar
• Keranen T, Jolkkomen J, Klosterskov- jensen, Menge GP et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand. 86,120–123 (1992).
   PubMed Web of Science ®Google Scholar
• Levy RH, Bishop F, Streeter AJ et al Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia 36, 47 (1995).
   Web of Science ®Google Scholar
• Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy. Epilepsy Res. 39,115–120 (2000).
   PubMed Web of Science ®Google Scholar
• Nakasa H, Nakamura H, Ono S et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. Clin. PharmacoL 54(2), 177–183 (1998).
   Google Scholar
• Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. Pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other anti-epileptics. Biol. Pharm. Bull. 16(7), 722–725 (1993).
   Google Scholar
• Mather GG, Carlson S, Trager WE Buchanan RA, Levy RH. Prediction of zonisamide interactions based on metabolic isozymes. Epilepsia 38,108 (1997).
   Google Scholar
• Lucke A, Musshoff U, Kohling R eta]. Gabapentin potentiation of the anti-epileptic effciacy of vigabatrin in an in vitro model of epilepsy. Br. j PharmacoL 124 (2), 370–376 (1998).
   Google Scholar
• Bourgeois BE Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity Epilepsia 29(4), 482–487 (1988).
   Google Scholar
• Bourgeois BE Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin. NeuropharmacoL 11(4), 348–359 (1988).
   Google Scholar
• Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55(4), 588–591 (2000).
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Russo ME Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40(8), 1141–1146, (1999).
   PubMed Web of Science ®Google Scholar
• Besag FM etal. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?Epllepsia 39(2), 183–187 (1998).
   Google Scholar
• Rambeck B, Salke-Treumann A, May T, Boenigk HE. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. Eur NeuroL 30(2), 79–83 (1990).
   Google Scholar
• McKee PJ, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 11(3), 193–198 (1992).
   PubMed Web of Science ®Google Scholar
• Albani F, Theodore WH, Washington P et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 32(1), 130–132 (1991).
   PubMed Web of Science ®Google Scholar
• Hossain M, Sallas W, Gasparini M et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology52\(Suppl. 2), A525 (1999).
   Google Scholar